All News
EULAR 2023: Featured Industry Presentations
EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR
Read Article
Colchicine and the Risk of Knee and Hip Replacement
Treatment of osteoarthritis is a major unmet need, as there are few therapies effective at pain control and no options for disease modification; yet a new trial in Annals of Internal Medicine suggest that chronic low dose colchicine may alter disease progression and lower the risk of of total knee and total hip replacements.
Read Article
#Precision medicine in #SLE #Interferon is not a good predictor of remission as it takes a LONG time to normalize in #Lupus @RheumNow @eular_org #EULAR2023 abst#OP https://t.co/JkWnk94bHu
Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2023 Annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
EULAR opens their meeting as a leader in #Rheumatology education and >5800 abstracts. A warm welcome for #EULAR2023 from the president! @RheumNow Opening ceremony. Impressive! https://t.co/RLQLQGOA8K
Janet Pope Janetbirdope ( View Tweet)
When does RA get complicated?
Many things can burden our patients, making their RA difficult to treat #EULAR2023 @RheumNow https://t.co/FM1UCNbmKr
David Liew drdavidliew ( View Tweet)
#EULAR2023 https://t.co/KwFnvzdNzz
Christian Ammitzbøll RheumTweeter ( View Tweet)
Researchers@of tomorrow. Winners of EULAR basic and epi and clinical abstract awards - young leaders! @RheumNow #EULAR2023 @eular_org https://t.co/VsV5aQpxjs
Janet Pope Janetbirdope ( View Tweet)
Delighted to be reporting for @RheumNow LIVE from Milan 🇮🇹 #EULAR2023 alongside my esteemed colleagues @drdavidliew @Janetbirdope @jeffsparks @synovialjoints @AurelieRheumo @bella_mehta 🙌🏻 Do follow us for Congress coverage 😃 https://t.co/tmD4vVWnQk
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 Please find my first article on Congress Preview of Promising New Therapies in #lupus #SLE @RheumNow
https://t.co/SFvhsP8QWO https://t.co/m5UwBGCXFB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
A full house for the #EULAR2023 Opening session @eular_org setting the tone for an exciting few days to come!
@RheumNow https://t.co/bZSIL78mU6
Aurelie Najm AurelieRheumo ( View Tweet)
Tuesday Night Rheumatology: POD 4: Rheumatoid Arthritis: Decisive Therapeutics https://t.co/GzLE2XLe1q
Dr. John Cush RheumNow ( View Tweet)
Watch: A Family History of Ankylosing Spondylitis
https://t.co/3U7DG8P52c https://t.co/lxial62ujS
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Evaluation of Sacroiliac Joint
RheumNow Live: Prof. Denis Poddubnyy, Charité University Hospital, Berlin
https://t.co/vH866d5sy6 https://t.co/zSMMBedyoG
Links:
Dr. John Cush RheumNow ( View Tweet)
Prevalence of PsA, Spondyloarthritis and Rheumatoid Arthritis in Norway
Recent reports have suggested a rising and unrecognized number of patients with PsA and axSpA compared to RA. This has implications on diagnosis and population care.
https://t.co/D0SvKP2MIa https://t.co/Gjh0oSZ5S2
Links:
Dr. John Cush RheumNow ( View Tweet)
Lupus Landmark Study to Accelerate Personalized Lupus Treatments
The Lupus Landmark Study, the largest study of its kind in lupus, will prospectively recruit and longitudinally follow 3,500 adults diagnosed with SLE.
https://t.co/nzCqk8AxK6 https://t.co/IS9OS08CmH
Links:
Dr. John Cush RheumNow ( View Tweet)
Tonight! The final Tuesday Night Rheumatology of May.
This webinar will feature highlights from these lectures followed by live audience Q & A:
Methotrexate Use: 50 Yr. Perspective
Myths vs Reality in RA
Biosimilars - Back on the Agenda
https://t.co/NRAtlQ96e3 https://t.co/j6WVyFacUc
Links:
Dr. John Cush RheumNow ( View Tweet)
TAS5315, BTK inhibitor, studied in 91 MTX refractory RA pts. Wk 12 ACR20 resp was 79% on TAS5315 vs 60% PBO (p=0.053); ACR50 (33 vs 13%) not signif. Adverse event equal betw grps, but 9 pts had bleeding on TAS5315 https://t.co/XYS0XRMJar https://t.co/ntGtahFf4T
Links:
Dr. John Cush RheumNow ( View Tweet)
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/8BMTmJqhPq https://t.co/BOMsk38KB2
Links:
Dr. John Cush RheumNow ( View Tweet)
Systematic review proves Keystones 60%/40%/20% response rule in biologic-naive #RA. 21 RCTs 1999-2017; For bio-naïve pts the ACR20/50/70 was 61.4%/37.8%/ 18.8%. For Bio-IR it was 48.5%/27.3%/12.9%- roughly 10pts lower. https://t.co/Xr3QEw278J https://t.co/OAfNghXlvB
Links:
Dr. John Cush RheumNow ( View Tweet)